GCPII in the prostate is called prostate specific membrane antigen (PSMA) [45] and although is expressed in both benign and cancerous prostate tissue, the degree of expression is higher in prostate cancer and increases with cancer severity [46]. Here, FOLH1 is linked to prostate carcinoma.